HEAD-TO-HEAD STUDY SHOWS ORAL FERRIC MALTOL (FERACCRU®) MAY BE AN ALTERNATIVE TREATMENT TO INTRAVENOUS (IV) FERRIC IRON, OFFERING A REAL ALTERNATIVE OPTION TO HOSPITAL ADMINISTRATION FOR PATIENTS WITH IRON DEFICIENCY ANAEMIA (IDA) AND INACTIVE INFLAMMATORY BOWEL DISEASE (IBD)
22 October 2019
We are proud to be able to help 22 million patients worldwide every year.
Founded in 1906, Norgine is a leading European specialist pharmaceutical company with a strong global network of partnerships.
This enables us to acquire, develop and commercialise innovative products that make a real difference to the lives of patients around the world.